|Year : 2016 | Volume
| Issue : 3 | Page : 339-341
Insurance coverage for male infertility care in the United States
James M Dupree
Department of Urology, Divisions of Andrology and Health Services Research and Department of Obstetrics and Gynecology, University of Michigan, 1500 E Medical Center Drive, 3875 Taubman Center, SPC 5330, Ann Arbor, MI 48109-5330, USA
|Date of Submission||25-Nov-2015|
|Date of Decision||25-Jan-2016|
|Date of Acceptance||08-Feb-2016|
|Date of Web Publication||29-Mar-2016|
Dr. James M Dupree
Department of Urology, Divisions of Andrology and Health Services Research and Department of Obstetrics and Gynecology, University of Michigan, 1500 E Medical Center Drive, 3875 Taubman Center, SPC 5330, Ann Arbor, MI 48109-5330
Source of Support: None, Conflict of Interest: None
Infertility is a common condition experienced by many men and women, and treatments are expensive. The World Health Organization and American Society of Reproductive Medicine define infertility as a disease, yet private companies infrequently offer insurance coverage for infertility treatments. This is despite the clear role that healthcare insurance plays in ensuring access to care and minimizing the financial burden of expensive services. In this review, we assess the current knowledge of how male infertility care is covered by insurance in the United States. We begin with an appraisal of the costs of male infertility care, then examine the state insurance laws relevant to male infertility, and close with a discussion of why insurance coverage for male infertility is important to both men and women. Importantly, we found that despite infertility being classified as a disease and males contributing to almost half of all infertility cases, coverage for male infertility is often excluded from health insurance laws. Excluding coverage for male infertility places an undue burden on their female partners. In addition, excluding care for male infertility risks missing opportunities to diagnose important health conditions and identify reversible or irreversible causes of male infertility. Policymakers should consider providing equal coverage for male and female infertility care in future health insurance laws.
Keywords: health policy; insurance; male infertility; public policy
|How to cite this article:|
Dupree JM. Insurance coverage for male infertility care in the United States. Asian J Androl 2016;18:339-41
| Introduction|| |
Infertility, defined as the inability to conceive after 12 months of regular, unprotected intercourse,  is very common. According to data from the National Survey of Family Growth, 6% of married women (aged 15-44 years) report being unable to get pregnant after 1 year of regular, unprotected intercourse.  In addition, 11% of all women (aged 15-44 years) report having impaired fecundity, which is defined as a physical difficulty getting pregnant or carrying a pregnancy to live birth.  Among women aged 25-44 years, 17% report ever using infertility services, but only 9% of men aged 25-44 years report ever using infertility services. 
Unlike other medical conditions, the diagnosis of infertility is applied to a pair of individuals: the two partners attempting to conceive a child. Therefore, discussions of female infertility must be accompanied by discussions of male infertility. However, 18%-27% of infertility couples (aged 15-44 years) report that the male partner did not undergo an infertility evaluation.  In this review, we will assess the current state of knowledge of how male infertility care is covered by insurance in the United States. We begin with an appraisal of the costs of infertility care, then examine the state insurance laws relevant to male infertility care, and close with a discussion of why insurance coverage for male infertility is important to both men and women.
| Costs of Infertility Care|| |
Infertility care is expensive. Smith et al. followed 391 women presenting for infertility care at a single institution. The patients were followed for 18 months and asked to report on the services they received. Using standardized costs, they found that 207 women received in vitro fertilization (IVF) treatments, with average costs of $30 274. Women who had intrauterine insemination (IUI) reported costs of $7704 and women who received only fertility medications reported costs of $1403. Even women who received no treatments reported average costs of $903. 
There are also high out-of-pocket costs associated with receiving infertility care. Wu et al. asked 332 couples to complete cost diaries during 18 months of receiving infertility care. Both male and female patients were included. Of the 178 couples who underwent IVF, the average out-of-pocket cost was $19 234. IUI out-of-pocket costs were $2623 and fertility medications cost an average of $912. 
Male infertility care is also expensive. 111 men pursing infertility care were asked to complete cost questionnaires at the end of their therapy. 64% of the men had out-of-pocket expenses of more than $15 000 whereas 16% reported expense of >$50 000. Overall, the male patients spent 16%-20% of their annual incomes on infertility-related expenses. In addition, 47% experienced financial strain due to infertility treatments and 46% had treatment options limited by cost.  With a 2013 median US household income of $51 939,  it is not surprising that these costs represented a substantial burden for male patients undergoing infertility treatments.
| Insurance Coverage for Infertility Care|| |
With high out-of-pocket costs for infertility care, it is easy to understand why insurance coverage of infertility care is important. Insurance has long been used as a tool to mitigate the costs associated with healthcare, and the passage of the Medicare law in 1965 provides relevant background. While the development of the Medicare bill was complicated and multifactorial, a major motivating factor was the need to relieve America's seniors of their high out-of-pocket healthcare expenses and expand their access to care. When he signed the Medicare bill on July 30, 1965, President Johnson, quoting President Truman, said:
"Millions of our citizens do not now have a full measure of opportunity to achieve and to enjoy good health. Millions do not now have protection or security against the economic effects of sickness. And the time has now arrived for action to help them attain that opportunity and to help them get that protection".
| Importance of Access to Male Infertility Care|| |
Insurance coverage for male infertility is important to both members of the infertile couple. Both the World Health Organization (WHO)  and the American Society of Reproductive Medicine (ASRM)  define infertility as a disease. Specifically, infertility is a disease because it is a "deviation from or interruption of the normal structure or function of any part, organ, or system of the body …".  Male factor infertility contributes to about half of all cases of infertility,  and the ASRM,  the National Institute for Health and Care Excellence,  and the Centers for Disease Control and Prevention  recommend that couples with infertility begin their work-ups together.
Evaluation and treatment for male infertility can benefit both members in an infertile couple. The goals of male infertility evaluations include (1) identifying and correcting reversible causes of male infertility, (2) identifying irreversible conditions that may be amenable to assisted reproductive techniques, and (3) identifying irreversible conditions in which the man's sperm are not obtainable.
Excluding insurance coverage for male infertility places an undue burden on female partners for the remainder of infertility treatments. Treatments for male infertility can downgrade the intensity of intervention required for the couple to achieve a pregnancy.  Interventions for men with infertility can also be cost-effective methods to help couples achieve pregnancies,  and skipping male factor treatments could lead to increased use of higher cost-assisted reproductive technologies. Finally, excluding male infertility evaluations risks missing opportunities to identify serious medical diseases associated with infertility and genetic conditions that may be transmitted to offspring. In a retrospective study from two academic medical centers, 6% of patients (33 of 536) presenting for infertility evaluations had important medical pathology identified such as 24 cases of cystic fibrosis mutations and two cases of cancer.  In addition, male infertility has been associated with an increased risk of cardiovascular disease,  testicular  and prostate cancer,  and early mortality. 
| Insurance Coverage for Female Infertility in the United States|| |
Evidence from the National Health Interview Survey confirms that in the modern era, a lack of insurance remains an important barrier to seeking needed care.  The Patient Protection and Affordable Care act is silent on federal infertility benefits,  which leaves decisions about mandating coverage for infertility care to individual states and employers.
Unfortunately, we know little about the current state of insurance coverage infertility care in the private insurance market. A 2006 survey of employers with ≥200 employees found that 63% of the 931 employers reported offering insurance coverage for infertility evaluations for their employees. Unfortunately, only 39% reported covering fertility medication therapy and only 22% reported covering IVF. 
At the state level, several publications have evaluated the impact of insurance mandates for female infertility care. Those studies found 15 states that mandate some form of insurance coverage for infertility, with various exceptions based on employer size, religious status, and type of insurance product. When examining the relationship between insurance mandates and infertility outcomes, previous authors have found that compared with states without infertility insurance mandates, state with insurance mandates perform more IVF cycles,  more IUI cycles,  and more hybrid cycles.  When examining IVF outcomes, states with insurance mandates were found to have fewer embryos transferred per cycle, a lower percent of live births per cycle, and a lower rate of multiples. 
| Insurance Coverage for Male Infertility in the United States|| |
While there have been multiple studies evaluating state mandates for female infertility coverage, only one study has examined state laws for male infertility mandates. We performed a primary, systematic review of state laws and found that of the 15 states with laws mandating coverage for female infertility care; only eight included any discussion of care for male infertility. 
Two states, Montana and West Virginia, have laws that mandate coverage for undefined infertility services in Health Maintenance Organization (HMO) plans. Six states, including California, Connecticut, Massachusetts, New Jersey, New York, and Ohio, also have laws that mandate some form of coverage for male infertility care ([Table 1]). In California, insurance companies must offer employers insurance plan options that include infertility coverage, but employers are not required to include those plans for their employees. Connecticut law requires that insurance plans cover diagnosis and treatment for individuals unable to produce conception. In Ohio, only HMO plans must provide for the diagnosis and treatment of testicular failure. Massachusetts, New Jersey, and New York laws offer the most comprehensive coverage for male infertility care, with Massachusetts' law also including coverage for sperm procurement and sperm banking. 
|Table 1: Summary of state laws with specific mandates for coverage of male infertility27 |
Click here to view
| International Insurance Coverage for Infertility|| |
While little has been published about the coverage of male infertility treatments in the United States, even less is known about insurance coverage for male infertility care internationally. In the Ontario province of Canada, three cycles of IVF are covered for women with "complete bilateral anatomical Fallopian tube More Details blockage that did not result from sterilization."  The province is considering expanding the indications for IVF, but again, there is no mention of male infertility evaluation or treatment in the announcements.  The Canadian province of Québec provides more comprehensive coverage of infertility evaluation and treatment for both partners. For male partners, there is coverage, with some exceptions, for basic infertility evaluations, surgical sperm retrieval, and sperm cryopreservation. 
In Europe, national policies about insurance coverage for infertility services vary from country to country.  However, in general, there is more widespread inclusion of infertility services in European national health plans as compared to state laws in the United States. 
| Conclusions|| |
Health insurance plays a critical role in ensuring access to healthcare and minimizing the financial burden of expensive services. Despite infertility being classified as a disease and males contributing to almost half of all infertility cases, coverage for male infertility is often excluded from US state laws that mandate infertility coverage. Evaluation and treatment for male infertility is expensive, and excluding coverage for male infertility places an undue burden on female partners. In addition, excluding care for male infertility evaluations risks missing opportunities to diagnose important health conditions and identify reversible or irreversible causes of male infertility. Policymakers should consider providing equal coverage for male and female infertility care in future health insurance laws.
| Author Contributions|| |
JMD was the author for this manuscript. He provided the conception and design, acquisition of data, and analysis and interpretation of data. He drafted, revised, and gave final approval for the published final version of the manuscript.
| Competing Interests|| |
James M. Dupree receives salary support from Blue Cross Blue Shield of Michigan for his position as Co-Director of the Michigan Value Collaborative and resource physician for the Michigan Urological Surgery Improvement Collaborative.
| References|| |
Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril
2008; 89: 1603.
Chandra A, Copen CE, Stephen EH. Infertility and impaired fecundity in the United States, 1982-2010: data from the National Survey of Family Growth. Natl Health Stat Report
2013; 67: 1-18.
Chandra A, Copen CE, Stephen EH. Infertility service use in the United States: data from the National Survey of Family Growth, 1982-2010. Natl Health Stat Report
2014; 73: 1-21.
Eisenberg ML, Lathi RB, Baker VL, Westphal LM, Milki AA, et al.
Frequency of the male infertility evaluation: data from the National Survey of Family Growth. J Urol
2013; 189: 1030-4.
Smith JF, Eisenberg ML, Glidden D, Millstein SG, Cedars M, et al.
Socioeconomic disparities in the use and success of fertility treatments: analysis of data from a prospective cohort in the United States. Fertil Steril
2011; 96: 95-101.
Wu AK, Odisho AY, Washington SL, Katz PP, Smith JF. Out-of-pocket fertility patient expense: data from a multicenter prospective infertility cohort. J Urol
2014; 191: 427-32.
Elliott PA, Hoffman J, Abad-Santos M, Herndon C, Katz PP, et al.
Out of pocket costs of male infertility care and associated financial strain. Urol Pract 2016. [In press].
Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology. Fertil Steril 2009; 92: 1520-4.
Thonneau P, Marchand S, Tallec A, Ferial ML, Ducot B, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). Hum Reprod 1991; 6: 811-6.
Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril 2015; 103: e44-50.
National Institute for Health and Clinical Excellence. Fertility: Assessment and Treatment for People with Fertility Problems. NICE Clinical Guideline 156; 2013. Available from: http://www.guidance.nice.org.uk/cg156
. [Last accessed on 2015 Oct 21].
Centers for Disease Control and Prevention. Infertility FAQs. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, U.S. Department of Health & Human Services. Available from: http://www.cdc.gov/reproductivehealth/infertility/
. [Last accessed on 2015 Oct 21].
Cayan S, Erdemir F, Ozbey I, Turek PJ, Kadioðlu A, et al. Can varicocelectomy significantly change the way couples use assisted reproductive technologies? J Urol 2002; 167: 1749-52.
Meng MV, Greene KL, Turek PJ. Surgery or assisted reproduction? A decision analysis of treatment costs in male infertility. J Urol 2005; 174: 1926-31.
Kolettis PN, Sabanegh ES. Significant medical pathology discovered during a male infertility evaluation. J Urol 2001; 166: 178-80.
Eisenberg ML, Park Y, Hollenbeck AR, Lipshultz LI, Schatzkin A, et al. Fatherhood and the risk of cardiovascular mortality in the NIH-AARP Diet and Health Study. Hum Reprod 2011; 26: 3479-85.
Walsh TJ, Croughan MS, Schembri M, Chan JM, Turek PJ. Increased risk of testicular germ cell cancer among infertile men. Arch Int Med 2009; 169: 351-6.
Walsh TJ, Schembri M, Turek PJ, Chan JM, Carroll PR, et al. Increased risk of high-grade prostate cancer among infertile men. Cancer 2010; 116: 2140-7.
Jensen TK, Jacobsen R, Christensen K, Nielsen NC, Bostofte E. Good semen quality and life expectancy: a cohort study of 43,277 men. Am J Epidemiol 2009; 170: 559-65.
Jain T, Harlow BL, Hornstein MD. Insurance coverage and outcomes of in vitro fertilization. N Engl J Med 2002; 347: 661-6.
Bitler MP, Schmidt L. Utilization of infertility treatments: the effects of insurance mandates. Demography 2012; 49: 125-49.
Dupree JM, Dickey JM, Lipshultz LI. Inequity between male and female coverage in state infertility laws. Fertil Steril 2016; [In Press] doi: 10.1016/j.fertnstert.2016.02.025.
Ziebe S, Devroey P. Assisted reproductive technologies are an integrated part of national strategies addressing demographic and reproductive challenges. Hum Reprod Update 2008; 14: 583-92.
Chambers GM, Sullivan EA, Ishihara O, Chapman MG, Adamson GD. The economic impact of assisted reproductive technology: a review of selected developed countries. Fertil Steril
2009; 91: 2281-94.
|This article has been cited by|
||Characterizing the Epidemiology and Provider Landscape of Male Infertility Care in the United States
| ||Richard J. Fantus,Kevin Alter,Cecilia Chang,Siddhant S. Ambulkar,Nelson E. Bennett,Brian T. Helfand,Robert E. Brannigan,Joshua A. Halpern |
| ||Urology. 2021; |
|[Pubmed] | [DOI]|
||Lack of trusted diagnostic tools for undetermined male infertility
| ||Swati Pandruvada,Rachel Royfman,Tariq A. Shah,Puneet Sindhwani,James M. Dupree,Samantha Schon,Tomer Avidor-Reiss |
| ||Journal of Assisted Reproduction and Genetics. 2021; |
|[Pubmed] | [DOI]|
||Clinical Efficacy of Prodom-Assisted Urokinase in the Treatment of Male Infertility Caused by Impaired Semen Liquefaction
| ||Kaiyi Mao,Zongping Chen,Mengzhi Li,Chengren Gou,Zidong Zhou,Yong Yan,Chao Chen,Tong Liu,Chenghong Zou,Yuhong Yao,Xu Li,Youlang Zhou |
| ||BioMed Research International. 2021; 2021: 1 |
|[Pubmed] | [DOI]|
||Evaluation, treatment, and insurance coverage for couples with male factor infertility in the US: A cross-sectional analysis of survey data
| ||Clara Helene Glazer,Jake Anderson-Bialis,Deborah Anderson-Bialis,Michael L. Eisenberg |
| ||Urology. 2020; |
|[Pubmed] | [DOI]|
||???????????? ?? ???????? ?????? ????????? ???????????? ??????? ????? ? ?????????? ???????????????????? ?????????? ??????????
| ||N. Ye. Gorban,I. B. Vovk,N. H. Hoida,O. V. Lynchak |
| ||???????? ????????? ? ????????????????? ????????. 2019; (3): 62 |
|[Pubmed] | [DOI]|
||The State of Menís Health Services in the Veterans Health Administration
| ||Michael Fenstermaker,Sujay Paknikar,Amarnath Rambhatla,Dana A Ohl,Ted A Skolarus,James M Dupree |
| ||Current Urology Reports. 2017; 18(11) |
|[Pubmed] | [DOI]|
||Men with Severe Oligospermia Appear to Benefit From Varicocele Repair: a Cost-Effectiveness Analysis of Assisted Reproductive Technology
| ||Justin M. Dubin,Aubrey B. Greer,Taylor P. Kohn,Thomas A. Masterson,Lunan Ji,Ranjith Ramasamy |
| ||Urology. 2017; |
|[Pubmed] | [DOI]|
||Advancement of male health is dependent upon updates to insurance coverage for infertility in the United States
| ||RyanP Smith,LarryI Lipshultz,JasonR Kovac |
| ||Asian Journal of Andrology. 2016; 18(3): 342 |
|[Pubmed] | [DOI]|